SCHEMBL2714739

SCHEMBL2714739

CC(C)(C)OC(=O)NC(Cc1ccc(-c2ccncc2)cc1)C(N)=O

nearest known ligand 0.56

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CTSS P25774 7/20 0.56
CTSK P43235 6/20 0.56
CYP17A1 P05093 1/20 0.53
REN P00797 3/20 0.50
CTSB P07858 2/20 0.47
CTSL P07711 1/20 0.47
ITGA4 P13612 2/20 0.47
ITGB7 P26010 2/20 0.47
BCL2 P10415 1/20 0.47
ITGB3 P05106 1/20 0.46
ITGA2B P08514 1/20 0.46
ACE P12821 1/20 0.46
AAK1 Q2M2I8 2/20 0.45
LHCGR P22888 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2714740 1.00 CTSS (0.56) CTSSCTSKCYP17A1RENCTSB
SCHEMBL2715763 0.89 CTSS (0.60) CTSSCTSKCYP17A1CTSBCTSL
SCHEMBL2310637 0.89 CTSS (0.60) CTSSCTSKCYP17A1CTSBCTSL
SCHEMBL2310645 0.89 CTSS (0.60) CTSSCTSKCYP17A1CTSBCTSL
SCHEMBL24438783 0.89 CTSS (0.69) CTSSCTSKRENCTSBCTSL
SCHEMBL13821431 0.89 CTSS (0.69) CTSSCTSKRENCTSBCTSL
SCHEMBL8182259 0.89 CTSS (0.69) CTSSCTSKRENCTSBCTSL
SCHEMBL17065417 0.87 ITGA4 (0.44) CTSSCTSKCYP17A1ITGA4ITGB7
SCHEMBL22147414 0.84 REN (0.67) CTSSCTSKRENCTSBCTSL
SCHEMBL9886038 0.83 CTSS (0.62) CTSSCTSKRENCTSBCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9902688-B2 Benzamides and nicotinamides as Syk modulators PORTOLA PHARMACEUTICALS, INC. (US) 2018-02-27 US disclosed
EP-3176154-A1 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS Portola Pharmaceuticals, Inc. (US) 2017-06-07 EP disclosed
US-20160318852-A1 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS ALEXION PHARMACEUTICALS, INC. 2016-11-03 US disclosed
US-9359375-B2 Benzamides and nicotinamides as Syk modulators PORTOLA PHARMACEUTICALS, INC. (US) 2016-06-07 US disclosed
US-20150038492-A1 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS ALEXION PHARMACEUTICALS, INC. 2015-02-05 US disclosed
US-8846928-B2 Benzamides and nicotinamides as Syk modulators PORTOLA PHARMACEUTICALS, INC. (US) 2014-09-30 US disclosed
EP-2635556-A2 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS Portola Pharmaceuticals, Inc. (US) 2013-09-11 EP disclosed
US-20120142671-A1 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-06-07 US disclosed
WO-2012061418-A2 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142671-A1 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS SYK, BTK, NADK CTSS 1406/4885CTSK 1202/4885CYP17A1 4053/4885
US-20160318852-A1 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS SYK, BTK, NADK CTSS 1406/4885CTSK 1202/4885CYP17A1 4053/4885
US-20150038492-A1 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS SYK, BTK, NADK CTSS 1406/4885CTSK 1202/4885CYP17A1 4053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.